Medistim ASA
OSE:MEDI

Watchlist Manager
Medistim ASA Logo
Medistim ASA
OSE:MEDI
Watchlist
Price: 251 NOK Market Closed
Market Cap: kr4.6B

Wall St Price Targets

MEDI Price Targets Summary
Medistim ASA

Wall Street analysts forecast MEDI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MEDI is 339.15 NOK with a low forecast of 328.25 NOK and a high forecast of 357 NOK.

Lowest Forecast
Price Target
328.25 NOK
31% Upside
Average Forecast
Price Target
339.15 NOK
35% Upside
Highest Forecast
Price Target
357 NOK
42% Upside
Medistim ASA Competitors:
Price Targets
GWH
ESS Tech Inc
494% Upside
BC
Brunello Cucinelli SpA
25% Upside
558
LK Technology Holdings Ltd
133% Upside
XAIR
Beyond Air Inc
745% Upside

Revenue
Forecast

11% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
11% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 3 years is 11%.

Gross Profit
Forecast

12% / Year
Past Growth
9% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
12% / Year
Past Growth
9% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 9%.

Operating Income
Forecast

16% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
16% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 14 years, the compound annual growth rate for Operating Income has been 16%. The projected CAGR for the next 3 years is 8%.

Pre-Tax Income
Forecast

17% / Year
Past Growth
-31% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
17% / Year
Past Growth
-31% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 17%. The projected CAGR for the next 1 year is -31%.

Net Income
Forecast

18% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
18% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 14 years, the compound annual growth rate for Net Income has been 18%. The projected CAGR for the next 3 years is 3%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is MEDI's stock price target?
Price Target
339.15 NOK

According to Wall Street analysts, the average 1-year price target for MEDI is 339.15 NOK with a low forecast of 328.25 NOK and a high forecast of 357 NOK.

What is the Revenue forecast for Medistim ASA?
Projected CAGR
11%

Over the last 14 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 3 years is 11%.

What is the Gross Profit forecast for Medistim ASA?
Projected CAGR
9%

Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 9%.

What is the Operating Income forecast for Medistim ASA?
Projected CAGR
8%

Over the last 14 years, the compound annual growth rate for Operating Income has been 16%. The projected CAGR for the next 3 years is 8%.

What is the Pre-Tax Income forecast for Medistim ASA?
Projected CAGR
-31%

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 17%. The projected CAGR for the next 1 year is -31%.

What is the Net Income forecast for Medistim ASA?
Projected CAGR
3%

Over the last 14 years, the compound annual growth rate for Net Income has been 18%. The projected CAGR for the next 3 years is 3%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett